Policy & Regulation
Kalytera Therapeutics cancels pre-clinical bone disease treatment development programs
17 April 2018 -

United States-based Kalytera Therapeutics has withdrawn its pre-clinical development programs in the treatment of bone disease to concentrate its resources on graft versus host disease and pain programs, it was reported yesterday.

The firm has determined that additional investments of time and resources in these programs would not be appropriate given the other opportunities in its product development pipeline.

The terminated programs were assessing three synthetic endocannabinoid compounds, KAL436, KAL439 and KAL671, in bone fracture healing, and osteogenesis imperfecta and osteoporosis. With regard to the termination of these programs, the company has withdrawn its License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, under which Kalytera had licensed rights to KAL436, KAL439 and KAL671.



Related Headlines